ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Nxera Pharma Company Ltd (PK)

Nxera Pharma Company Ltd (PK) (SOLTF)

6,00
-0,37
(-5,81%)
Geschlossen 04 Juli 10:00PM

Nxera Pharma Company Ltd (PK) (SOLTF) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
6,00
( -5,81% )
Gebot
5,35
Fragen
6,54
Volumen
1.150
6,00 Tagesbereich 6,00
4,90 52-Wochen-Bereich 7,94
Marktkapitalisierung
Handelsende
6,37
Handelsbeginn
6,00
Letzte Trade
1150
@
6
Letzter Handelszeitpunkt
Finanzvolumen
US$ 6.900
VWAP
6,00
Durchschnittliches Volumen (3 Mio.)
US$ 1.058.156
Ausgegebene Aktien
92.612.178
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-8,97
Gewinn pro Aktie (EPS)
-110,34
Erlöse (LTM)
34,23B
Nettogewinn (LTM)
-9,98B

Über Nxera Pharma Company Ltd (PK)

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ fo... Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. The company’s products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Minato, Japan
Gegründet
1990
Nxera Pharma Company Ltd (PK) is listed in the Healthcare sector of the OTC Markets with ticker SOLTF. The last closing price for Nxera Pharma (PK) was US$6,37. Over the last year, Nxera Pharma (PK) shares have traded in a share price range of US$ 4,90 to US$ 7,94.

Nxera Pharma (PK) currently has 92.612.178 shares in issue. The market capitalisation of Nxera Pharma (PK) is US$555,67 million. Nxera Pharma (PK) has a price to earnings ratio (PE ratio) of -8.97.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10006000CS
4-0.185-2.991107518196.1856.3765006.2035CS
12-0.53-8.116385911186.537.945.5161876.4066779CS
260.8115.60693641625.197.945.1543026.38407472CS
52-0.2-3.225806451616.27.944.919136.31136843CS
156-4.38-42.196531791910.3813.524.912828.55212333CS
260-10.3203-63.23596992716.320322.7824.9144411.29736742CS

SOLTF - Frequently Asked Questions (FAQ)

What is the current Nxera Pharma Company Ltd (PK) share price?
The current share price of Nxera Pharma Company Ltd (PK) is US$ 6,00
How many Nxera Pharma Company Ltd (PK) shares are in issue?
Nxera Pharma Company Ltd (PK) has 92.612.178 shares in issue
What is the market cap of Nxera Pharma Company Ltd (PK)?
The market capitalisation of Nxera Pharma Company Ltd (PK) is USD 555,67M
What is the 1 year trading range for Nxera Pharma Company Ltd (PK) share price?
Nxera Pharma Company Ltd (PK) has traded in the range of US$ 4,90 to US$ 7,94 during the past year
What is the PE ratio of Nxera Pharma Company Ltd (PK)?
The price to earnings ratio of Nxera Pharma Company Ltd (PK) is -8,97
What is the cash to sales ratio of Nxera Pharma Company Ltd (PK)?
The cash to sales ratio of Nxera Pharma Company Ltd (PK) is 2,68
What is the registered address of Nxera Pharma Company Ltd (PK)?
The registered address for Nxera Pharma Company Ltd (PK) is Midtown East, Minato, Tokyo, 107-0052
What is the Nxera Pharma Company Ltd (PK) website address?
The website address for Nxera Pharma Company Ltd (PK) is www.nxera.life
Which industry sector does Nxera Pharma Company Ltd (PK) operate in?
Nxera Pharma Company Ltd (PK) operates in the Biotechnology & Life Sciences sector

SOLTF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen